Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways
Collaborations, Agility Also Key
Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.
US FDA’s approval after a near-unanimous advisory committee vote against Biogen’s Alzheimer’s drug is central to many critics’ arguments, but the acting commissioner says that panel did not vote on the issue of accelerated approval, and that airing of internal agency disagreements could have influenced committee members.
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.